Design of experiments to optimize gallic acid carbon-based nanoparticle synthesis for enhanced photodynamic therapy in cancer cells.

IF 2.9 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Koranat Dechsri, Supusson Pengnam, Thapakorn Charoenying, Boonnada Pamornpathomkul, Chaiyakarn Pornpitchanarong, Prasopchai Patrojanasophon, Tanasait Ngawhirunpat, Theerasak Rojanarata, Praneet Opanasopit
{"title":"Design of experiments to optimize gallic acid carbon-based nanoparticle synthesis for enhanced photodynamic therapy in cancer cells.","authors":"Koranat Dechsri, Supusson Pengnam, Thapakorn Charoenying, Boonnada Pamornpathomkul, Chaiyakarn Pornpitchanarong, Prasopchai Patrojanasophon, Tanasait Ngawhirunpat, Theerasak Rojanarata, Praneet Opanasopit","doi":"10.1080/10837450.2025.2597342","DOIUrl":null,"url":null,"abstract":"<p><p>Carbon-based nanoparticles (CNPs) have attracted significant attention as photosensitizers for photodynamic therapy (PDT) due to their biocompatibility, facile synthesis, and ability to generate reactive oxygen species (ROS). In this study, green-synthesized gallic acid CNPs (GACNPs) were optimized and characterized for their physicochemical properties and biomedical potential. GACNPs exhibited no cytotoxicity to normal cells at concentrations up to 250 µg/mL, demonstrating excellent biocompatibility. Under LED light irradiation (350-700 nm, 0.124 W/cm<sup>2</sup>, 10 min), GACNPs efficiently generated ROS, as assessed by photodynamic activity and intracellular ROS detection, confirming their photosensitizing function. The anticancer efficacy of GACNPs was evaluated in HeLa and MDA-MB-231 cell lines, revealing IC<sub>50</sub> values of 2.92 ± 0.14 µg/mL (exposure) versus 3.74 ± 0.22 µg/mL (non-exposure) for HeLa and 2.62 ± 0.24 µg/mL (exposure) versus 4.14 ± 0.19 µg/mL (non-exposure) for MDA-MB-231 cells, indicating significantly enhanced cytotoxicity upon light exposure. Furthermore, both cell lines showed that GACNPs significantly enhanced the anticancer effect upon exposure compared to the GA solution. Apoptosis assays showed 64% cell death after exposure, compared to 47% without exposure, in HeLa cells, and 93% cell death after exposure, compared to 74% in MDA-MB-231 cells. These findings demonstrate that GACNPs are promising nano-photosensitizers for PDT-based cancer therapy, combining low cytotoxicity with high ROS-mediated anticancer efficacy.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"48-67"},"PeriodicalIF":2.9000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Development and Technology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10837450.2025.2597342","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/12/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Carbon-based nanoparticles (CNPs) have attracted significant attention as photosensitizers for photodynamic therapy (PDT) due to their biocompatibility, facile synthesis, and ability to generate reactive oxygen species (ROS). In this study, green-synthesized gallic acid CNPs (GACNPs) were optimized and characterized for their physicochemical properties and biomedical potential. GACNPs exhibited no cytotoxicity to normal cells at concentrations up to 250 µg/mL, demonstrating excellent biocompatibility. Under LED light irradiation (350-700 nm, 0.124 W/cm2, 10 min), GACNPs efficiently generated ROS, as assessed by photodynamic activity and intracellular ROS detection, confirming their photosensitizing function. The anticancer efficacy of GACNPs was evaluated in HeLa and MDA-MB-231 cell lines, revealing IC50 values of 2.92 ± 0.14 µg/mL (exposure) versus 3.74 ± 0.22 µg/mL (non-exposure) for HeLa and 2.62 ± 0.24 µg/mL (exposure) versus 4.14 ± 0.19 µg/mL (non-exposure) for MDA-MB-231 cells, indicating significantly enhanced cytotoxicity upon light exposure. Furthermore, both cell lines showed that GACNPs significantly enhanced the anticancer effect upon exposure compared to the GA solution. Apoptosis assays showed 64% cell death after exposure, compared to 47% without exposure, in HeLa cells, and 93% cell death after exposure, compared to 74% in MDA-MB-231 cells. These findings demonstrate that GACNPs are promising nano-photosensitizers for PDT-based cancer therapy, combining low cytotoxicity with high ROS-mediated anticancer efficacy.

实验设计优化没食子酸碳基纳米颗粒合成,以增强癌细胞的光动力治疗。
碳基纳米颗粒(CNPs)由于其生物相容性、易于合成和产生活性氧(ROS)的能力,作为光动力治疗(PDT)的光敏剂受到了广泛的关注。本研究对绿色合成没食子酸CNPs (GACNPs)进行了优化,并对其理化性质和生物医学潜力进行了表征。在250µg/mL浓度下,GACNPs对正常细胞无细胞毒性,表现出良好的生物相容性。在LED光照射(350-700 nm, 0.124 W/cm2, 10 min)下,通过光动力学活性和细胞内ROS检测,GACNPs能有效生成ROS,证实了其光敏功能。在HeLa和MDA-MB-231细胞系中评估了GACNPs的抗癌作用,发现HeLa细胞的IC50值为2.92±0.14µg/mL(暴露),而MDA-MB-231细胞的IC50值为3.74±0.22µg/mL(未暴露),MDA-MB-231细胞的IC50值为2.62±0.24µg/mL(暴露),而MDA-MB-231细胞的IC50值为4.14±0.19µg/mL(未暴露),表明光暴露后细胞毒性显著增强。此外,两种细胞系显示,与GA溶液相比,暴露后的GACNPs显著增强了抗癌作用。凋亡试验显示,HeLa细胞暴露后细胞死亡率为64%,而未暴露时为47%;暴露后细胞死亡率为93%,而MDA-MB-231细胞为74%。这些发现表明,GACNPs具有低细胞毒性和高ros介导的抗癌功效,是一种很有前景的基于pdp的癌症治疗纳米光敏剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.90
自引率
2.90%
发文量
82
审稿时长
1 months
期刊介绍: Pharmaceutical Development & Technology publishes research on the design, development, manufacture, and evaluation of conventional and novel drug delivery systems, emphasizing practical solutions and applications to theoretical and research-based problems. The journal aims to publish significant, innovative and original research to advance the frontiers of pharmaceutical development and technology. Through original articles, reviews (where prior discussion with the EIC is encouraged), short reports, book reviews and technical notes, Pharmaceutical Development & Technology covers aspects such as: -Preformulation and pharmaceutical formulation studies -Pharmaceutical materials selection and characterization -Pharmaceutical process development, engineering, scale-up and industrialisation, and process validation -QbD in the form a risk assessment and DoE driven approaches -Design of dosage forms and drug delivery systems -Emerging pharmaceutical formulation and drug delivery technologies with a focus on personalised therapies -Drug delivery systems research and quality improvement -Pharmaceutical regulatory affairs This journal will not consider for publication manuscripts focusing purely on clinical evaluations, botanicals, or animal models.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书